ライフサイエンスコーパス: clinical cure

1 The outcome was resolution of disease (clinical "cure").

2 ration was not independently associated with clinical cure.

3 g hospital mortality censored at 30 days and clinical cure.

4 with mortality; however, it had no effect on clinical cure.

5 ermittent administration with improvement in clinical cure.

6 d treatment-related factors on mortality and clinical cure.

7 was recurrence during the 28 days following clinical cure.

8 et criteria for noninferiority for achieving clinical cure.

9 d intentionally create mixed chimerism and a clinical cure.

10 ate well with response to treatment and with clinical cure.

11 of 400 mg of fluconazole were necessary for clinical cure.

12 Secondary outcomes were 90-day survival, clinical cure 14 days post antibiotic cessation, alive o

13 The primary endpoint was sustained clinical cure 30 days after end of treatment (day 55 for

14 tended-pulsed fidaxomicin achieved sustained clinical cure 30 days after end of treatment, compared w

15 composite of microbiological eradication and clinical cure 5-9 days after treatment in the microbiolo

16 The primary outcome was clinical cure 7 to 10 days after the end of treatment.

17 The primary outcome was clinical cure 7 to 10 days after the end of treatment.

18 Secondary end points were clinical cure 7 to 14 days after the end of treatment, a

19 escue antibiotic); (2) investigator-assessed clinical cure 7-14 days after end of treatment; and (3)

20 .4 percentage points); investigator-assessed clinical cure, 79.6% versus 80.0% (95% CI for the differ

21 al [CI], -7.5 to 2.0), investigator-assessed clinical cure (82.7% vs 80.5%; 95% CI, -2.6 to 7.0), and

22 All the patients were followed up for clinical cure after 10 days of treatment.

23 ost T cell-intact patients show long-lasting clinical cure after treatment despite residual intracell

24 Clinical cure and recurrence outcomes were analyzed by s

25 To understand the inconsistency between the clinical cure and the presence of "residual disease" at

26 ttent injection have failed to show superior clinical cures and for the most part microbiological suc

27 The efficacy outcomes included clinical cure at 24 hours and time to last unformed stoo

28 Clinical cure at 24 hours occurred in 81.4%, 78.3%, and

29 The primary outcome was clinical cure at day 7, which was assessed from diaries

30 The primary outcome measure was clinical cure at end of therapy visit (EOT) at Days 9 to

31 The primary end point was clinical cure at test-of-cure visit 28-35 days after ran

32 of a sustained clinical response, defined as clinical cure at the end of treatment and no recurrence

33 Rates of clinical cure at the last evaluation were similar among

34 The primary endpoint was clinical cure at the test-of-cure visit (21-25 days afte

35 The primary endpoint was clinical cure at the test-of-cure visit (8-15 days after

36 cal intent-to-treat population, the rates of clinical cure at the test-of-cure visit were 86.8% in th

37 The overall proportions of patients with a clinical cure at the test-of-cure visit were similar wit

38 For each CMS course, clinical cure, bacteriological clearance, daily serum cr

39 obial treatment had no significant effect on clinical cure, bacteriological cure, pathogen clearance

40 Clinical cure by day 7 occurred in 128 (83%) of 155 chil

41 a, and cancer were inversely associated with clinical cure by multivariate analysis.

42 daxomicin regimen might facilitate sustained clinical cure by prolonging C difficile suppression and

43 and follow-up visits and were classified as clinical cure, clinical failure, or indeterminate/missin

44 ents (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24 (62.5%) in the auto

45 mined a priori in the per-protocol group was clinical cure, defined as absence of these clinical fail

46 In pathogen-specific analyses, clinical cure did not differ by arm, nor did microbiolog

47 ve been shown to persist in their host after clinical cure, establishing the risk of disease reactiva

48 in MICs of baseline isolates did not predict clinical cure, failure, or recurrence of C. difficile in

49 The rates of hospital mortality and clinical cure for the continuous versus intermittent inf

50 highly likely to increase the probability of clinical cure from infection and suppress the emergence

51 zolid is superior to vancomycin in achieving clinical cure in patients with nosocomial pneumonia.

52 ive predictive value (94.3%-100.0%) for late clinical cure, including among hospitalized patients.

53 Clinical cure (<5 PMNs/HPF with or without urethral symp

54 Outcomes evaluated consisted of clinical cure, microbiological eradication, and side eff

55 In the per-protocol population, clinical cure occurred in 182 (83.5%) of 218 participant

56 the modified intention-to-treat population, clinical cure occurred in 189 (76.2%) of 248 participant

57 In the per-protocol population, clinical cure occurred in 487 of 524 participants (92.9%

58 The primary end point was clinical cure of CDI at end of treatment, and a secondar

59 the modified intention-to-treat population, clinical cure of the abscess occurred in 507 of 630 part

60 The primary outcome was clinical cure of the abscess, assessed 7 to 14 days afte

61 of post-treatment specimens does not predict clinical cure or relapse.

62 , 70%-82%) receiving doxycycline experienced clinical cure (P = .40).

63 The clinical cure rate at test-of-cure for hospital-acquired

64 The overall clinical cure rate at the 30-day visit with the intent-t

65 The primary efficacy variable was clinical cure rate at the test-of-cure visit (days 25-50

66 The clinical cure rate of patients infected with the epidemi

67 rimethoprim-sulfamethoxazole yields a higher clinical cure rate of uncomplicated cellulitis than ceph

68 ed as having not responded to treatment, the clinical cure rate was 83% (124/150) for ciprofloxacin c

69 The clinical cure rate was 85% after the treatment.

70 The clinical cure rate with ceftazidime-avibactam plus metro

71 993 isolates, with a concomitant drop in the clinical cure rate.

72 ution MICs, E-test MICs, disc diffusion, and clinical cure rate.

73 Clinical cure rates at test-of-cure were 80% (146 of 183

74 to demonstrate statistical noninferiority in clinical cure rates at the test-of-cure visit (24-32 day

75 The difference in clinical cure rates between the groups was -0.80% (95% C

76 ysis of the trials for CABP (FOCUS 1 and 2), clinical cure rates for the ceftaroline group were numer

77 Notably, the clinical cure rates in ME patients with methicillin-resi

78 Preliminary data suggest that clinical cure rates may be lower among women with uncomp

79 as associated with greater bacteriologic and clinical cure rates than a 14-day trimethoprim-sulfameth

80 sing results, including fidaxomicin (similar clinical cure rates to vancomycin, with lower recurrence

81 ents with ESBL-producing Enterobacteriaceae, clinical cure rates were 95.8% (23/24) and 88.5% (23/26)

82 Clinical cure rates were 96% (109 of 113) for the ciprof

83 patients with CABP caused by S. pneumoniae, clinical cure rates were markedly higher in the ceftarol

84 so have less bacterial eradication and lower clinical cure rates when treated with TMP-SMX for an inf

85 Clinical cure rates with ceftazidime-avibactam plus metr

86 zolid is compared with vancomycin only, then clinical cure relative risk is 1.00 (95% confidence inte

87 he linezolid vs. glycopeptide analysis shows clinical cure relative risk of 1.01 (95% confidence inte

88 : death, bacterial cultures, and presumptive clinical cure score.

89 Continued bacteriologic and clinical cure, such that alternative antimicrobial drugs

90 Clinical cure was 52.4% (111 of 212) and 49.5% (109 of 2

91 lost to follow-up were considered as having clinical cure was 93% (139/150) for ciprofloxacin compar

92 Clinical cure was higher in the continuous group (70% vs

93 Clinical cure was observed in 23 cases (82.1%).